22:27:35 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaFirst North Stockholm
IndustriLäkemedel & Handel
AlzeCure Pharma är ett läkemedelsbolag. Bolaget är inriktade mot forskning och utveckling av läkemedel som används för diverse hjärnsjukdomar, med störst fokus mot Alzheimers sjukdom. Teknologin och forskningen utgår ifrån egen läkemedelsplattform, där bolaget utvecklar olika symptomlindrande läkemedelskandidater. Huvudkontoret ligger i Huddinge.


2022-11-10 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-19 Ordinarie utdelning ALZCUR 0.00 SEK
2022-05-17 Årsstämma 2022
2022-05-05 Kvartalsrapport 2022-Q1
2022-02-24 Bokslutskommuniké 2021
2021-11-10 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-18 Ordinarie utdelning ALZCUR 0.00 SEK
2021-05-17 Årsstämma 2021
2021-05-05 Kvartalsrapport 2021-Q1
2021-02-26 Bokslutskommuniké 2020
2020-11-17 Kvartalsrapport 2020-Q3
2020-08-25 Kvartalsrapport 2020-Q2
2020-05-22 Ordinarie utdelning ALZCUR 0.00 SEK
2020-05-20 Årsstämma 2020
2020-04-29 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-11-15 Kvartalsrapport 2019-Q3
2019-08-31 Kvartalsrapport 2019-Q2
2019-05-23 Ordinarie utdelning ALZCUR 0.00 SEK
2019-05-22 Årsstämma 2019
2019-05-01 Kvartalsrapport 2019-Q1
2019-02-28 Bokslutskommuniké 2018
2022-07-05 10:00:00

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that an abstract on clinical study data with its leading drug candidate NeuroRestore ACD856, which is being developed with a focus on Alzheimer's disease, has been accepted for a poster presentation at AAIC 2022, which this year will be held in San Diego, USA, from July 31 to August 4.

The abstract, titled Results From a Multiple Ascending Dose Study in Healthy Volunteers of ACD856, a Positive Modulator of Neurotrophin Trk-Receptors, will be presented at the international Alzheimer's conference AAIC by project leader Kristin Önnestam. Co-authors include Boel Nilsson, Project leader & Clinical Trial Manager, Dr. Johan Sandin, CSO at AlzeCure, Dr. Matthias Rother, Medical Program Director, and Dr. Märta Segerdahl, CMO at AlzeCure.

The presentation will include new data from the clinical MAD study, the main purpose of which is to evaluate the safety, tolerability and pharmacokinetics (PK) of repeated and increasing doses of the NeuroRestore substance ACD856. ACD856 or placebo has been given orally repeatedly for one week to 24 healthy subjects divided into 3 groups in incremental doses. ACD856, which is a positive modulator of both NGF/TrkA and BDNF/TrkB mediated signaling, has in preclinical studies been shown to improve cognition and memory and is developed primarily for the treatment of Alzheimer's disease.

"This is a recognition of ACD856, which is the leading drug candidate in the NeuroRestore platform, and its focus on Alzheimer's disease where there is a great medical need," said Kristin Önnestam, project leader for ACD856.

"These new data are very important and we are pleased with this opportunity to present our data at such a well-known international and in an area of increased interest and societal need such as Alzheimer's and cognitive disorders," said Martin Jönsson, CEO of AlzeCure Pharma AB.

The abstract and the poster will be available on AlzeCure's website after the presentation (https://www.alzecurepharma.se/en/presentations-and-interviews/).